|
|
Taiwan Academic Institutional Repository >
Browse by Title
|
Showing items 542996-543005 of 2348609 (234861 Page(s) Totally)
<< < 54295 54296 54297 54298 54299 54300 54301 54302 54303 54304 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-05-07T06:48:04Z |
Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells
|
Huang H.-L.; Chen Y.-C.; Huang Y.-C.; KAI-CHIEN YANG; Pan H.y.; Shih S.-P.; Chen Y.-J. |
| 中國醫藥大學 |
2014-05-27 |
Lapatinib induces IL-6 expression via MAPK pathway in triple-negative breast cancer cells
|
蕭宇君(Hsiao Yu-Chun);陳孟良(Mong-Liang Chen);陳韻如(Chen Yun-Ju);湯智昕(Tang Chih-Hsin);黃偉謙(Wei-Chien Huang)* |
| 臺大學術典藏 |
2018-09-10T14:52:06Z |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
|
KUN-HUEI YEH; Satoh, T. and Doi, T. and Ohtsu, A. and Tsuji, A. and Omuro, Y. and Mukaiyama, A. and Kobayashi, M. and Miwa, H. and Xu, R.-H. and Sun, G.-P. and Xu, J.-M. and Wang, J.-W. and Li, J. and Qin, S.-K. and Feng, J.-F. and Chung, H.C. and Bang, Y.-J. and Chung, I.-J. and Yeh, K.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
|
Satoh T.;Doi T.;Ohtsu A.;Tsuji A.;Omuro Y.;Mukaiyama A.;Kobayashi M.;Miwa H.;Xu R.-H.;Sun G.-P.;Xu J.-M.;Wang J.-W.;Li J.;Qin S.-K.;Feng J.-F.;Chung H.C.;Bang Y.-J.;Chung I.-J.;Kun-Huei Yeh; Satoh T.; Doi T.; Ohtsu A.; Tsuji A.; Omuro Y.; Mukaiyama A.; Kobayashi M.; Miwa H.; Xu R.-H.; Sun G.-P.; Xu J.-M.; Wang J.-W.; Li J.; Qin S.-K.; Feng J.-F.; Chung H.C.; Bang Y.-J.; Chung I.-J.; KUN-HUEI YEH |
| 國立成功大學 |
2012-02-18 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
|
Baselga, Jose; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Fauria, Karine; Van Dooren, Veerle; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horvath, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Kunz, Georg; Sohn, Joo Hyuk; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymyr; Pusztai, Lajos; Untch, Michael; Gelber, Richard D.; Piccart-Gebhart, Martine |
| 國立臺灣大學 |
2014 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
|
de Azambuja, Evandro; Holmes, Andrew P.; Piccart-Gebhart, Martine; Holmes, Eileen; Di Cosimo, Serena; Swaby, Ramona F.; Untch, Michael; Jackisch, Christian; Lang, Istvan; Smith, Ian; Boyle, Frances; Xu, Binghe; Barrios, Carlos H.; Perez, Edith A.; Azim, Hatem A., Jr.; Kim, Sung-Bae; Kuemmel, Sherko; Huang, Chiun-Sheng; Vuylsteke, Peter; Hsieh, Ruey-Kuen; Gorbunova, Vera; Eniu, Alexandru; Dreosti, Lydia; Tavartkiladze, Natalia; Gelber, Richard D.; Eidtmann, Holger; Baselga, Jose; 黃俊升 |
| 臺大學術典藏 |
2018-09-10T15:02:13Z |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
|
de Azambuja, E. and Holmes, A.P. and Piccart-Gebhart, M. and Holmes, E. and Di Cosimo, S. and Swaby, R.F. and Untch, M. and Jackisch, C. and Lang, I. and Smith, I. and Boyle, F. and Xu, B. and Barrios, C.H. and Perez, E.A. and Azim, H.A. and Kim, S.-B. and Kuemmel, S. and Huang, C.-S. and Vuylsteke, P. and Hsieh, R.-K. and Gorbunova, V. and Eniu, A. and Dreosti, L. and Tavartkiladze, N. and Gelber, R.D. and Eidtmann, H. and Baselga, J.; CHIUN-SHENG HUANG |
| 臺大學術典藏 |
2020-03-23T07:19:13Z |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
|
Xu B.; Boyle F.; Smith I.; Jackisch C.; Lang I.; Untch M.; Swaby R.F.; Di Cosimo S.; Holmes E.; Piccart-Gebhart M.; Holmes A.P.; De Azambuja E.;Holmes A.P.;Piccart-Gebhart M.;Holmes E.;Di Cosimo S.;Swaby R.F.;Untch M.;Jackisch C.;Lang I.;Smith I.;Boyle F.;Xu B.;Barrios C.H.;Perez E.A.;Azim H.A.;Kim S.-B.;Kuemmel S.;Chiun-Sheng Huang;Vuylsteke P.;Hsieh R.-K.;Gorbunova V.;Eniu A.;Dreosti L.;Tavartkiladze N.;Gelber R.D.;Eidtmann H.;Baselga J.; De Azambuja E.; Barrios C.H.; Perez E.A.; Azim H.A.; Kim S.-B.; Kuemmel S.; CHIUN-SHENG HUANG; Vuylsteke P.; Hsieh R.-K.; Gorbunova V.; Eniu A.; Dreosti L.; Tavartkiladze N.; Gelber R.D.; Eidtmann H.; Baselga J. |
| 中國醫藥大學 |
2013-12-31 |
Lapatinib 脫靶效應增強HDAC抑制劑對三陰性乳癌治療效果之探討
|
葉名焮(Ming-Hsin, Alex, Yeh);黃偉謙(Wei-Chien Huang) |
| 中國醫藥大學 |
2013-11 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
|
(Yun-Ju Chen);葉名焮(Ming-Hsin, Alex, Yeh);游孟潔(Meng-Chieh Yu);魏雅鈴(Ya-Ling Wei);(Wen-Shu Chen);(Jhen-Yu Chen);(Chih-Yu Shih);涂智彥(Chih-Yen Tu);陳家弘(Chia-Hung Chen);夏德椿(Te-Chun Hsia);(Pei-Hsuan Chien);(Shu-Hui Liu);余永倫(Yung-Luen Yu);黃偉謙(Wei-Chien Huang)* |
Showing items 542996-543005 of 2348609 (234861 Page(s) Totally)
<< < 54295 54296 54297 54298 54299 54300 54301 54302 54303 54304 > >>
View [10|25|50] records per page
|
